Battle of the biologics: How to survive
The onward march of biologics has shaped a brave new world for drug manufacturers with conflicting rules and regulations and an eclectic mix of individual players to contend with. Biosimilars are more pervasive than ever; complex and hard-fought patent disputes are commonplace; regulators are struggling to keep pace with change. Against this chaotic backdrop, how should biologics manufacturers protect and grow their business?
Based on in-depth interviews with eight biologics experts from leading biotechnology, consulting, marketing and healthcare-associated companies, Defending Against Biosimilars: Strategies To Retain Market Share provides a clear path forward. Taking perspectives from both the US and EU, this report delves into the threats facing the biologics marketplace and identifies what must happen for biologics companies to not only survive, but effectively compete and ultimately thrive.
Report available for immediate download -- place your order today
Report available for immediate download -- place your order today
The biologics debate has got fiercer in recent months and interested onlookers could be forgiven for thinking that some drug manufacturers are investing more in patent protection, litigation and lawyers than they are in development. Take away the concerns and rhetoric and there is no disputing the fact that biologics present exciting opportunities for patients and physicians, as well as for drug manufacturers of all sizes and specialisms. A tightening of regulatory standards around several aspects of the biological-biosimilar divide will ultimately provide some sense of order, but gaining consensus is slow and whilst the discussions are underway, the world continues to turn. In this current state of flux, some biologics players will emerge as winners. The question is: which ones?
Find answers to these and many more important questions — download the report today
“As hard as it may be to accept for some originators, there is a place for biosimilars. However, the regulatory/payer world needs to ensure a level playing field. When a biosimilar comes to market, one should let the originator compete on equal terms.”
Previous Marketing Director of a large pharmaceutical company
“We'll see how the market shapes up, but I think the coming few years will be interesting to watch what risks big companies are taking and how much revenue they are generating using the biosimilars.”
Rakesh Dixit, Vice President of R&D, MedImmune
Critical insights from these and many other respected experts available for immediate download —place your order here
Report available for immediate download — place your order here
This critical intelligence is available for immediate download —order your copy here
Need more information? Contact a consultant for an executive summary and sample pages from the report.
Battle of the biologics: How to survive
The onward march of biologics has shaped a brave new world for drug manufacturers with conflicting rules and regulations and an eclectic mix of individual players to contend with. Biosimilars are more pervasive than ever; complex and hard-fought patent disputes are commonplace; regulators are struggling to keep pace with change. Against this chaotic backdrop, how should biologics manufacturers protect and grow their business?
Based on in-depth interviews with eight biologics experts from leading biotechnology, consulting, marketing and healthcare-associated companies, Defending Against Biosimilars: Strategies To Retain Market Share provides a clear path forward. Taking perspectives from both the US and EU, this report delves into the threats facing the biologics marketplace and identifies what must happen for biologics companies to not only survive, but effectively compete and ultimately thrive.
Report available for immediate download -- place your order today
Report available for immediate download -- place your order today
The biologics debate has got fiercer in recent months and interested onlookers could be forgiven for thinking that some drug manufacturers are investing more in patent protection, litigation and lawyers than they are in development. Take away the concerns and rhetoric and there is no disputing the fact that biologics present exciting opportunities for patients and physicians, as well as for drug manufacturers of all sizes and specialisms. A tightening of regulatory standards around several aspects of the biological-biosimilar divide will ultimately provide some sense of order, but gaining consensus is slow and whilst the discussions are underway, the world continues to turn. In this current state of flux, some biologics players will emerge as winners. The question is: which ones?
Find answers to these and many more important questions — download the report today
“As hard as it may be to accept for some originators, there is a place for biosimilars. However, the regulatory/payer world needs to ensure a level playing field. When a biosimilar comes to market, one should let the originator compete on equal terms.”
Previous Marketing Director of a large pharmaceutical company
“We'll see how the market shapes up, but I think the coming few years will be interesting to watch what risks big companies are taking and how much revenue they are generating using the biosimilars.”
Rakesh Dixit, Vice President of R&D, MedImmune
Critical insights from these and many other respected experts available for immediate download —place your order here
Report available for immediate download — place your order here
This critical intelligence is available for immediate download —order your copy here
Need more information? Contact a consultant for an executive summary and sample pages from the report.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved